Image source: Shutterstock

Highlights

  • Revenue Growth and Weather Impacts: Q1 revenue rose 9.2% to $471.4 million, despite a $22 million hit from severe weather and wildfires.

  • AI Momentum and iCAD Acquisition: Digital Health revenue jumped 31.1%; RadNet signed a deal to acquire iCAD, boosting AI-driven breast cancer screening capabilities.

  • Upward Guidance Revision: 2025 full-year revenue guidance raised to $1.835–$1.885 billion and Adjusted EBITDA to $268–$276 million.

RadNet, Inc. (NASDAQ:RDNT), a national leader in outpatient diagnostic imaging has reported its financial results for the first quarter of 2025, tempered by weather-related disruptions. At the same time, the company has raised its full-year financial guidance and made strategic moves to enhance its role in AI-powered cancer diagnostics.

RadNet posted total revenue of $471.4 million, up 9.2% year-over-year from $431.7 million in Q1 2024. However, Adjusted EBITDA declined 20.6% to $46.4 million, primarily due to a $15 million impact from Southern California wildfires and severe winter weather that also dented revenue by approximately $22 million. The net loss for the quarter widened to $37.9 million, or $(0.51) per share, compared to a $2.8 million loss in the same period last year.

Despite these headwinds, CEO Dr. Howard Berger expressed confidence in the company's trajectory, citing a significant rebound in business during March and continued momentum into April and May. “Advanced imaging volumes, including PET/CT scans, have shown impressive growth, and our AI-powered breast cancer detection program is achieving significant adoption,” Berger said.

RadNet’s Digital Health segment was a standout performer, with revenue climbing 31.1% to $19.2 million and Adjusted EBITDA rising slightly to $3.7 million. The segment is powered by the Enhanced Breast Cancer Detection (EBCD) program, which has now reached over 40% nationwide adoption. The technology improves radiologist productivity while detecting cancers that may otherwise go unnoticed. Discussions with commercial payors about EBCD reimbursement are ongoing, with RadNet expecting progress by year-end.

Adding further momentum to its AI strategy, RadNet in April signed a definitive agreement to acquire iCAD, Inc., a leader in AI-based cancer detection. Once completed, the acquisition will integrate iCAD’s solutions across RadNet’s network, expanding its reach to over 1,500 healthcare providers performing more than 8 million mammograms annually in 50+ countries.

Procedural volumes in advanced imaging continued their upward trend, with PET/CT volumes growing 22.9% year-over-year, driven by demand for prostate and brain imaging. MRI and CT volumes were also up by 8.4% and 8.3%, respectively.

Encouraged by operational resilience and AI-driven growth, RadNet revised its 2025 guidance upward. The company now expects revenue between $1.835 billion and $1.885 billion and Adjusted EBITDA between $268 million and $276 million, both modest increases from earlier projections. Capital expenditure guidance was also raised to a range of $145 million to $155 million.